Portal de Periódicos da CAPES

68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients

2017; Impact Journals LLC; Volume: 8; Issue: 7 Linguagem: Inglês

10.18632/oncotarget.14691

1949-2553

Shiming Zang, Guoqiang Shao, Can Cui, Tiannv Li, Yue Huang, Xiaochen Yao, Fan Qiu, Zejun Chen, Jin Du, Ruipeng Jia, Hongbin Sun, Zichun Hua, Jun Tang, Feng Wang,

Peptidase Inhibition and Analysis

// Shiming Zang 1, * , Guoqiang Shao 1, * , Can Cui 1 , Tian-Nv Li 2 , Yue Huang 3 , Xiaochen Yao 1 , Qiu Fan 1 , Zejun Chen 4 , Jin Du 5 , Ruipeng Jia 6 , Hongbin Sun 6 , Zichun Hua 7 , Jun Tang 8 , Feng Wang 1 1 Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China 2 Department of Nuclear Medicine, PET Centre, No. 1 Hospital Affiliated to Nanjing Medical University, Nanjing 210029, China 3 Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China 4 Department of Nuclear Medicine, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin 214400, China 5 Department of Technology Development, China Isotope Radiation Corporation, No. 1 Nansixiang, Sanlihe, West District, Beijing 100045, China 6 Department of Urology, Nanjing Medical University, Nanjing 210006, China 7 The State Key Laboratory of Pharmaceutical Biotechnology, Department of Biochemistry, College of Life Sciences, Nanjing University, Nanjing 210006, China 8 Department of Nuclear Medicine, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China * These authors have contributed equally to this work Correspondence to: Feng Wang, email: fengwangcn@hotmail.com Hongbin Sun, email: docshb@126.com Keywords: treatment-naïve prostate cancer, prostate-specific membrane antigen, metastatic castrate-resistant prostate cancer, staging, risk stratification Received: July 22, 2016 Accepted: December 27, 2016 Published: January 17, 2017 ABSTRACT We evaluated the clinical utility of 68 Ga-PSMA-11 PET/CT for staging and risk stratification of treatment-naïve prostate cancer (PCa) and metastatic castrate-resistant prostate cancer (mCRPC). Twenty-two consecutive patients with treatment-naïve PCa and 18 with mCRPC were enrolled. 68 Ga-PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic lesions, and bone scans were used for evaluation bone metastasis. Among the 40 patients, 37 (92.5% [22 treatment-naïve PCa, 15 mCRPC]) showed PSMA-avid lesions on 68 Ga-PSMA-11 images. Only 3 patients with stable mCRPC after chemotherapy were negative for PSMA. The sensitivity, specificity and accuracy of 68 Ga-PSMA-11 imaging were 97.3%, 100.0% and 97.5%, respectively. The maximum standardized uptake (SUV max ) of prostatic lesions was 17.09 ± 11.08 and 13.33 ± 12.31 in treatment-naïve PCa and mCRPC, respectively. 68 Ga-PSMA-11 revealed 105 metastatic lymph nodes in 15 patients; the SUV max was 16.85 ± 9.70 and 7.54 ± 5.20 in treatment-naïve PCa and mCRPC, respectively. 68 Ga-PSMA-11 PET/CT also newly detected visceral metastasis in 9 patients (22.5%) and bone metastasis in 29 patients (72.5%). 68 Ga-PSMA-11 PET/CT exhibits potential for staging and risk stratification in naïve PCa, as well as improved sensitivity for detection of lymph node and remote metastasis.